

## Evaluation of periodontal health in patients taking Atorvastatin

Kosar Rezaei Talarposhti<sup>1</sup>, Babak Amoian<sup>2✉</sup>, Ali Akbar Moghadamnia<sup>3</sup>, Soraya Khafri<sup>4</sup>

1. Dental Student, Student Research Committee, Babol University of Medical Sciences, Babol, IR Iran. **ORCID** (0000-0002-0494-4012)
2. Associate Professor, Oral Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, IR Iran.
3. Professor, Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, IR Iran.
4. Assistant Professor, Infertility and Reproductive Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, IR Iran.

✉**Corresponding Author:** Babak Amoian, Faculty of Dentistry, Babol University of Medical Sciences, Babol, IR Iran.

**Email:** amoian@yahoo.com

**Tel:** +981132291409 **ORCID** (0000-0002-7809-6466)

Received: 19 Mar 2018

Accepted: 30 Sept 2018

### Abstract

**Introduction:** Periodontal disease as a chronic inflammatory condition is more prevalent in adults. Considering the anti-inflammatory effect of statins and the need to find out the effects of these drugs on the prevention and treatment of periodontal diseases, this study was conducted to investigate the role of atorvastatin in periodontal health.

**Material & Methods:** In this cross sectional study the effect of atorvastatin on plaque index, probing pocket depth (PPD), gingival index (GI) and bleeding on probing (BOP) index were examined. Patients with plaque index between 1 and 2 were included in the study, and those who had taken atorvastatin for at least 3 months were selected as the case group and those who had not taken atorvastatin were considered as the control group.

**Results:** A total of 138 patients (50 patients for the atorvastatin group and 88 patients for the control group) were included. The mean probing pocket depth in the atorvastatin group was  $2.03 \pm 0.35$  mm and that in the control group was  $2.8 \pm 0.31$  mm ( $p=0.335$ ). The mean bleeding index in the atorvastatin group was  $0.20 \pm 0.14$  and compared to the control group was  $0.20 \pm 0.17$  ( $p < 0.001$ ). The GI index in the atorvastatin group was  $1.29 \pm 0.33$ , compared to the control group was  $1.20 \pm 0.40$  ( $p=0.218$ ).

**Conclusion:** The results of this study indicate the positive effect of the use of atorvastatin on reducing the bleeding on probing index in patients taking this drug. The probing pocket depth index and gingival index were not significantly different between the atorvastatin group and the group not taking this drug.

**Keywords:** Atorvastatin, Periodontitis, Hyperlipidemias

**Citation for article:** Rezaei Talarposhti K, Amoian B, Moghadamnia AK, Khafri S. Evaluation of periodontal health in patients taking atorvastatin. Caspian J Dent Res 2018; 7:30-7.

## بررسی سلامت پریدونتال در بیماران مصرف کننده داروی آتورواستاتین

کوثر رضائی تالارپشتی<sup>۱</sup>، بابک عمویان<sup>۲\*</sup>، علی اکبر مقدم نیا<sup>۳</sup>، ثریا خفری<sup>۴</sup>

۱. دانشجوی دندانپزشکی، کمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی بابل، بابل، ایران.
۲. دانشیار، مرکز تحقیقات سلامت و بهداشت دهان، پژوهشکده سلامت، دانشگاه علوم پزشکی بابل، بابل، ایران.
۳. استاد، مرکز تحقیقات سرطان، پژوهشکده سلامت، دانشگاه علوم پزشکی بابل، بابل، ایران.
۴. استادیار، مرکز تحقیقات بهداشت باروری و ناباروری، پژوهشکده سلامت، دانشگاه علوم پزشکی بابل، بابل، ایران.

\*نویسنده مسئول: بابک عمویان، دانشکده دندانپزشکی، دانشگاه علوم پزشکی بابل، بابل، ایران.  
پست الکترونیکی: amoian@yahoo.com تلفن: +۹۸۱۱۳۲۲۹۱۴۰۹

### چکیده

**مقدمه:** بیماری پریدونتال بیماری مزمن التهابی است که در بزرگسالان شایع تر است. با توجه به اثر ضد التهابی استاتین ها و نیاز به پیدا کردن اثرات این داروها در پیشگیری و درمان بیماری های پریدونتال، این مطالعه به منظور بررسی اثر آتورواستاتین در سلامت پریدونتال انجام شد.

**مواد و روش ها:** در این مطالعه اثر آتورواستاتین بر سلامت پریدونتال با ارزیابی شاخص پلاک، عمق پاکت (PPD)، شاخص لته (GI) و خونریزی حین پروبینگ (BOP) مورد بررسی قرار گرفت. بیماران با شاخص پلاک بین ۱ تا ۲ در مطالعه قرار گرفتند و افرادی که آتورواستاتین را برای حداقل ۳ ماه مصرف کرده بودند به عنوان گروه مورد و افرادی که آتورواستاتین را مصرف نکرده بودند به عنوان گروه شاهد در نظر گرفته شدند.

**یافته ها:** در مجموع ۱۳۸ بیمار (۵۰ بیمار در گروه آتورواستاتین و ۸۸ بیمار در گروه شاهد) شامل می شدند. میانگین عمق پاکت در گروه آتورواستاتین  $۲/۰۳ \pm ۰/۳۵$  میلی متر و در گروه شاهد  $۲/۸ \pm ۰/۳۱$  میلیمتر بود ( $p = 0.335$ ). میانگین شاخص خونریزی در گروه آتورواستاتین  $۰/۲۰ \pm ۰/۱۴$  و در مقایسه با گروه شاهد  $۰/۲۰ \pm ۰/۱۷$  بود، ( $p < 0.001$ ) شاخص GI در گروه آتورواستاتین  $۱/۲۹ \pm ۰/۳۳$  بود در مقایسه با گروه شاهد  $۱/۲۰ \pm ۰/۴۰$  ( $p = 0.218$ ).

**نتیجه گیری:** نتایج این مطالعه نشان دهنده تاثیر استفاده از آتورواستاتین بر کاهش خونریزی حین پروبینگ در بیماران مصرف کننده این دارو است. عمق پاکت و شاخص لته ای بین گروه آتورواستاتین و گروهی که این دارو را مصرف نمی کردند تفاوت معنی داری نداشت.

**واژگان کلیدی:** آتورواستاتین، پریدونتیت، هیپرلیپیدمی

### Introduction

Statin drugs (HMG-CoA inhibitors) inhibit 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase in the mevalonate (MVA) pathway. [1] The pathway of MVA is a very important metabolic one in eukaryotes and many bacteria, which ultimately leads to the production of many important compounds such as cholesterol and isoprenoids (terpenes such as lycopene

and carotene). In the human liver, the conversion of HMG-CoA to mevalonic acid is influenced by HMG-CoA reductase enzyme in the initial stages of cholesterol production. Therefore, the competitive inhibition of this enzyme by static drugs reduces blood cholesterol levels. [2] Statins have been developed to lower serum cholesterol levels [3] and successfully used to control and treat coronary artery diseases. [4-6]

Recently, cholesterol-independent or “pleiotropic” effects of statins have attracted the most attention and it is expected that the anti-inflammatory pleiotropic effects result from the inhibition of isoprene modulation from an inflammatory signal transducer. [7, 8] Much attention has been paid to these potential effects including antithrombotic, antioxidant, anti-inflammatory, anti-proliferative and immune modulatory effects. In addition, statins enhance the expression of the bone morphogenic protein-2 (BMP-2) and stimulate the proliferation of *osteoblasts* [1] Furthermore, the decrease in LDL-C level, which is a pleiotropic characteristic of statins, indicates their anti-inflammatory properties. [7, 9-13] Periodontal disease is caused by the function of certain microorganisms. Microorganisms and their products stimulate the inflammatory cells, produce cytokines, release proteolytic enzymes and activate osteoclasts. Although some studies have focused on the topical and systemic use of statins in the treatment of periodontal disease, many aspects of this disease still require further investigation. [5] Gingivitis is one of the most common topical inflammatory diseases in adults [14, 15], leading to periodontitis as a continuous inflammatory process that results in the destruction of periodontal tissue if left untreated. [16] This moderate inflammation can impose significant loads on the cardiovascular system, is involved in cardiovascular disease [16-19] and has been shown to be associated with systemic inflammation. [20]

Since cardiovascular disease is also a common disease among adults, and various drugs including statins are administered for the prevention and treatment of their disease as well as considering the anti-inflammatory effect of statins and the need to find out the effects of these drugs on the prevention and treatment of periodontal diseases, this cross-sectional study was performed to investigate the relationship between the use of atorvastatin and clinical symptoms of chronic periodontitis.

## Materials & Methods

After ethical approval was given by Babol University of Medical Sciences (Mubabol.REC.1395.170). A total of 138 patients were selected from the patients admitted to Shahid Beheshti and Rouhani Hospitals of Babol University of Medical Sciences (Babol, Iran) and entered into the study. Patients were informed about the study process. To

determine the anti-inflammatory pleiotropic effect of atorvastatin, the patients were divided into two groups, the first group included those who used 10 or 20 mg/daily of atorvastatin for at least 3 months and the second group was those who did not use this drug with almost identical conditions. The patients were similar in terms of oral hygiene, and all of them regularly used toothbrushes.

The patients' plaque index was examined and those with equal plaque indices (between 1 and 2) were compared in the current study. The two groups were equal in terms of age, ranging from 40 to 60 years and the exclusion criteria were smokers and patients with systemic diseases which affect periodontium, with the history of periodontal therapy for 6 months and with the history of antibiotic therapy since 1 month ago. The selected subjects in the atorvastatin group did not differ significantly in terms of the duration of this drug use.

The indices were tested via examination on Ramfjord teeth using a periodontal probe, catheter and mirror. These teeth were the maxillary right first molar, maxillary left first incisor, maxillary left first premolar, mandibular left first molar, mandibular right first incisor and mandibular right first premolar. [21] All of the patients were examined in the hospitals using a steady flashlight. Information such as age, gender, smoking and statin use were collected from the patients' records before they were examined. The patients' history of other diseases including diabetes mellitus and rheumatoid arthritis as well as history of the use of other medications were recorded.

The plaque index was performed based on the Loe and Silness method. [22] The total score of each tooth was divided into 4 and the plaque index of each subject was obtained by adding the plaque index of all examined teeth and dividing it into the number of the examined teeth. The plaque index was between 0 and 3. It was evaluated in patients and was equal in both case and control groups, and finally, only those who had the plaque index between 1 and 2 were included in the present study. The probing pocket depth (PPD) or the distance from the gingival margin to the most coronal level of the junctional epithelium was measured using a probe on the Ramfjord teeth in the six areas of Mesiobuccal, Midbuccal, Distobuccal, Distolingual, Midlingual, and Mesiolingual. [21]

The gingival index (GI) was performed based on the Loe and Silness method. [22] The total score of each tooth is divided into 4 and the gingival index of each

subject is obtained by adding the gingival index of all examined teeth and dividing it into the number of the examined teeth. In this index, based the average of the obtained numbers, the status of the gingivitis is classified into three mild, moderate and severe degrees.

The bleeding on probing (BOP) index was performed based on Barnett's proposed method. In this method, the periodontal probe slowly moved in the gingival sulcus at the buccal and lingual surfaces, the duration needed for bleeding was measured, the sum of the indicators of the 4 surfaces of the 6 teeth examined is divided into 24 and the obtained bleeding index of each patient was a number between 0 and 3. [23]

Independent-sample t-test and paired-sample t-test were used to compare the data of the two groups using SPSS 21.  $P < 0.05$  was statistically considered as a significant difference.

## Results

A total of 138 patients were entered into the present study. The atorvastatin group included 50 patients with an average age of  $49.12 \pm 4.58$  years and the control group was 88 patients with an average age of  $48.95 \pm 3.55$  years.

Table 1 shows the mean periodontal pocket depth in teeth 1, 4 and 6 for both atorvastatin and control groups. In general, the mean periodontal pocket depth in the atorvastatin group was  $2.33 \pm 0.35$  mm, whereas it was  $2.8 \pm 0.31$  mm in the control group, which was not significant between the two groups ( $p = 0.335$ ).

There was no significant difference between two groups in pocket depth according to the Mann-Whitney test.

**Table 1. The mean ( $\pm$ SD) periodontal pocket depth for atorvastatin and control groups**

Mean periodontal pocket depth and standard deviation per millimeters	Atorvastatin Group	control group	Pvalue
Tooth 1	$0.32 \pm 1.56$	$0.29 \pm 1.59$	0.555
Tooth 4	$0.45 \pm 2.01$	$0.40 \pm 2.05$	0.556
Tooth 6	$0.58 \pm 2.54$	$0.53 \pm 2.62$	0.472
Total	$0.35 \pm 2.03$	$0.31 \pm 2.08$	0.335

The mean scores of the bleeding on probing index for tooth 6 in the atorvastatin group and control group were  $0.24 \pm 0.24$  and  $0.26 \pm 0.30$ , respectively. This mean

score according to the Mann-Whitney test two groups was not statistically significant ( $p = 0.718$ ).

The bleeding index for tooth 4 in the atorvastatin group was  $0.15 \pm 0.17$ , while it was  $0.28 \pm 0.25$  in the control group, which was statistically significant ( $p = 0.003$ ). The results suggested that the mean score of the bleeding index was higher in control group than atorvastatin group. The mean ( $\pm$ SD) of bleeding index for tooth 1 in the atorvastatin group was  $0.21 \pm 0.24$ , but it was  $0.35 \pm 0.32$  in the control group ( $p = 0.014$ ). The mean bleeding index in the atorvastatin group was  $0.20 \pm 0.14$ , whereas it was  $0.20 \pm 0.17$  in the control group ( $p < 0.001$ ).

The mean GI index was  $1.29 \pm 0.33$  and  $1.20 \pm 1.40$  in the atorvastatin and control groups, respectively, indicating no statistically significant difference ( $p = 0.132$ ). Frequency and percentage of the GI index in both groups are presented in table 2.

**Table 2. Frequency and percentage of the GI index in both groups**

		Atorvastatin Group	control group
GI index	mild	frequency 43	65
		percentage 87.8%	79.3%
	moderate	frequency 12.2%	17
		percentage	20.7%

## Discussion

Periodontal disease is a chronic inflammatory disease characterized by the release of cytokines such as TNF- $\alpha$  and IL-1 $\beta$ . [24-27] Several studies have been conducted to investigate the possible association between serum lipid profile and periodontitis. [20, 27-33] Nevertheless, investigations on the optimal role of statin drugs in periodontal tissues have led to controversial reports in some studies. [27, 32, 33] A retrospective study conducted by Lindy et al. [34] illustrated that the use of statin drugs was significantly associated with fewer symptoms of periodontal inflammatory injuries. Other studies have indicated that the serum pre-inflammatory cytokines and tissue fluid may be responsible for the relationship between periodontal disease and hyperlipidemia. [35-37]

The present study aimed at evaluating the periodontal health in patients taking atorvastatin and pocket depth index between the two groups. The results indicated no significant difference between the mean pocket depth in the atorvastatin group and control

group. Lindy et al. and Sangwan et al. compared the pocket depth between patients taking and patients not taking statins.<sup>[34, 38]</sup> Both studies demonstrated a significant difference between the two groups in terms of this index, which is inconsistent with the findings of the present study.

This cross sectional study also showed that the difference of bleeding index between the atorvastatin group and the control group was significant so that the bleeding index was significantly higher in the control group than atorvastatin group. Moreover, a study conducted by Sayar et al.<sup>[39]</sup> illustrated that the hyperlipidemia patients treated with statin drugs for at least 3 months had a better periodontal status compared to those in the control group in terms of periodontal clinical parameters such as the bleeding on probing index. This positive effect of statin on the bleeding index and other clinical parameters of periodontal disease was similarly indicated in other studies.<sup>[34, 38-44]</sup>

A comparison of the GI parameter between the two groups showed that the difference in this parameter is not statistically significant, which is consistent with the result of Sangwan et al.<sup>[38]</sup> Since statins have anti-inflammatory effects, it can be construed that this lack of difference between the two groups is indicative of the positive effect of atorvastatin on maintaining the inflammatory status of the gingiva in the group taking this drug. However, the level of inflammatory proteins or other inflammatory markers has not been measured in the current study and this suggestion is based on previous studies conducted on the effect of statins on inflammation through measurement of inflammatory markers, histological analysis and genetic evaluation.<sup>[45, 46]</sup>

Several known biological characteristics of lipids may be responsible for the periodontal changes observed and in some cases, may explain the role of periodontal protection by statins in this study. The first explanation is that the improved serum lipid levels as a result of using the atorvastatin can be useful for periodontal tissues, because higher levels of lipid lead to relatively weaker situation of the periodontal status.<sup>[20, 28-31]</sup> The hyperlipidemia status accelerates the pre-inflammatory status and the decreased lipid levels of serum as a result of using the atorvastatin can by itself be effective in modulating inflammation.<sup>[47-50]</sup> The second explanation is that the direct pleiotropic effect of atorvastatin can lead to apparent benefits of periodontal health.

This hypothesis is supported by previous studies, representing that the statins reduce the matrix metalloproteinase stimulated release<sup>[51]</sup>, tumor necrosis factor (TNF- $\alpha$ ) and C-reactive protein (CRP).<sup>[52]</sup> The pharmacokinetic analysis of statins has estimated plasma accumulation of about  $10^{-9}$  and  $10^{-7}$  mol in recipients of oral systemic doses<sup>[53]</sup> and shown that the drug level in the tissue fluid of the gum is nearly 10-100 times as much as plasma.<sup>[54]</sup> As a result, the topical anti-inflammatory effects on the oral tissue can be expected after oral administration of clinical doses. Although both of the described mechanisms can synergistically lead to the observed effects, the direct interpretation of the information obtained from this study cannot be linked to any of these mechanisms precisely, because the patients' serum lipid levels as well as inflammatory factors have not been measured due to the existing limitations. The results of the present study should be interpreted based on the limitations that the researchers encountered. The first limitation was the cross-sectional type of this research, explaining the cause-effect relationship.

Another limitation was related to the lack of access to the baseline periodontal status data before the patients started taking atorvastatin. Despite the fact that all patients had a clear range of atorvastatin treatment duration, the exact period of each patient treated with this drug was not statistically analyzed for the interpretation of the results. In addition, periodontal indicators were evaluated only on four surfaces of Ramfjord teeth.

## Conclusion

The results of this study indicate that the use of atorvastatin can be effective in reducing the bleeding on probing index in patients who use this medication. The pocket depth index and GI were not significantly different between atorvastatin users and non-users. Since statins have anti-inflammatory effects, this lack of difference between the two groups can be interpreted to indicate the beneficial effect of atorvastatin on maintaining the gingivitis in the group using this medication.

## Acknowledgements

This study was supported by the Research Council of Babol University of Medical Sciences. The authors

would like to thank the Council for assisting in carrying out this study.

**Funding:** This study was a part of research project (Grant No.9542922), supported and funded by Babol University of Medical Sciences.

**Conflict of interest:** We declare no conflict of interest.

### Authors' Contributions

The study was designed by Babak Amoian, and Kosar Rezaei defined the conceptual content of the research. The study data were collected by Kosar Rezaei. Statistical analysis and interpretation of data were accomplished by Soraya Khafri. Preparation of manuscript was performed by Kosar Rezaei, its editing and revision were done by Babak Amoian and Ali Akbar Moghadamnia contributed to the design and implementation of the research.

### References

1. Dalcico R, de Menezes AM, Deocleciano OB, Oriá RB, Vale ML, Ribeiro RA, et al. Protective mechanisms of simvastatin in experimental periodontal disease. *J Periodontol* 2013;84:1145.
2. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. *Arterioscler Thromb Vasc Biol* 1995;15:678-82.
3. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. *FEBS Lett* 1976;72:323-6.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;344:1383-9.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. west of scotland coronary prevention study group. *N Engl J Med* 1995;333:1301-7.
6. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive

- patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003;361:1149-58.
7. Liao JK, Laufs U. Pleiotropic effects of statins. *Annu Rev Pharmacol Toxicol* 2005;45:89-118.
8. Meisel P, Kroemer HK, Nauck M, Holtfreter B, Kocher T. Tooth loss, periodontitis, and statins in a population-based follow-up study. *J Periodontol* 2014;85:e160.
9. Lindy S, Turto H, Uitto J, Helin P, Lorenzen I. Injury and repair in arterial tissue in the rabbit. Analysis of DNA, RNA, hydroxyproline, and lactate dehydrogenase in experimental arteriosclerosis. *Circ Res* 1972;30:123-30.
10. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). *N Engl J Med* 1976;295:369-77.
11. Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts). *N Engl J Med* 1976;295:420-5.
12. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005;352:1685-95.
13. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med* 1997;336:973-9.
14. Albandar JM, Rams TE. Global epidemiology of periodontal diseases: an overview. *Periodontol* 2000 2002;29:7-10.
15. Southerland JH, Taylor GW, Moss K, Beck JD, Offenbacher S. Commonality in chronic inflammatory diseases: periodontitis, diabetes, and coronary artery disease. *Periodontol* 2000 2006;40:130-43.
16. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. *Lancet* 2005;366:1809-20.
17. Deliygyris EN, Madianos PN, Kadoma W, Marron I, Smith SC Jr, Beck JD. Periodontal disease in patients with acute myocardial infarction: prevalence and contribution to elevated C-reactive protein levels. *Am Heart J* 2004;147:1005-9.
18. D'Aiuto F, Ready D, Tonetti MS. Periodontal disease and C-reactive protein-associated cardiovascular risk. *J Periodontal Res* 2004 Aug;39:236-41.

19. D'Aiuto F, Parkar M, Nibali L, Suvan J, Lessem J, Tonetti MS. Periodontal infections cause changes in traditional and novel cardiovascular risk factors: results from a randomized controlled clinical trial. *Am Heart J* 2006;151:977-84.
20. Nibali L, D'Aiuto F, Griffiths G, Patel K, Suvan J, Tonetti MS. Severe periodontitis is associated with systemic inflammation and a dysmetabolic status: a case-control study. *J Clin Periodontol* 2007;34:931-7.
21. Newman MG, Takei HH, Klokkevold PR Carranza FA, editors. *Carranza's clinical periodontology*. 11th ed. St. Louis, Mo : Saunders Elsevier; 2012. p.157
22. Loe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. *Acta Odontol Scand* 1963;21:533-51.
23. Barnett M L, Ciancio S G , Mather M L. The modified papillary bleeding index: Comparison with gingival index during the resolution of gingivitis. *J Prev Dent* 1980; 6: 135-8.
24. Magán-Fernández A, Papay-Ramírez L, Tomás J, Marfil-Álvarez R, Rizzo M, Bravo M, et al. Association of simvastatin and hyperlipidemia with periodontal status and bone metabolism markers. *J Periodontol* 2014;85:1408-15.
25. Stein SH, Dean IN, Rawal SY, Tipton DA. Statins regulate interleukin-1 $\beta$ -induced RANKL and osteoprotegerin production by human gingival fibroblasts. *J Periodontol Res* 2011;46:483-90.
26. Singh KP, Dodwad V, Dhariwal G. Simvastatin and periodontal regeneration. *J Pharm Biomed Sci* 2012;21:1-4.
27. Valentaviciene G, Paipalienė P, Nedzelskiene I, Žilinskas J, Anuseviciene OV. The relationship between blood serum lipids and periodontal condition. *Stomatologija* 2006;8:96-100.
28. Pohl A. Hyperlipidemia, atherosclerosis, and oral inflammatory diseases. *Acta Angiologica* 1995;1: 133-7. [In Japanese]
29. Morita M, Horiuchi M, Kinoshita Y, Yamamoto T, Watanabe T. Relationship between blood triglyceride levels and periodontal status. *Community Dent Health* 2004;21:32-6.
30. Monteiro AM, Jardini MA, Alves S, Giampaoli V, Aubin EC, Figueiredo Neto AM, et al. Cardiovascular disease parameters in periodontitis. *J Periodontol* 2009;80:378-88.
31. Taleghani F, Shamaei M, Shamaei M. Association between Chronic Periodontitis and Serum Lipid Levels. *Acta Med Iran* 2010; 48:47-50.
32. Machado AC, Quirino MR, Nascimento LF. Relation between chronic periodontal disease and plasmatic levels of triglycerides, total cholesterol and fractions. *Braz Oral Res* 2005;19:284-9.
33. Korhonen S, Saxlin T, Suominen L, Jula A, Knuutila M, Ylöstalo P. Serum cholesterol ratios and periodontal infection: results of the health 2000 Survey. *J Clin Periodontol* 2011;38:787-94.
34. Lindy O, Suomalainen K, Mäkelä M, Lindy S. Statin use is associated with fewer periodontal lesions: A retrospective study. *BMC Oral Health* 2008;8:16.
35. Fentoğlu O, Kirzioğlu FY, Özdem M, Koçak H, Sütçü R, Sert T. Proinflammatory cytokine levels in hyperlipidemic patients with periodontitis after periodontal treatment. *Oral Dis* 2012;18:299-306.
36. Fentoğlu Ö, Köroğlu BK, Hiçyılmaz H, Sert T, Özdem M, Sütçü R , et al. Pro-inflammatory cytokine levels in association between periodontal disease and hyperlipidaemia. *J Clin Periodontol* 2011;38:8-16.
37. Fentoğlu O, Köroğlu BK, Kara Y, Doğan B, Yılmaz G, Sütçü R, et al. Serum lipoprotein-associated phospholipase A<sub>2</sub> and C-reactive protein levels in association with periodontal disease and hyperlipidemia. *J Periodontol* 2011;82:350-9.
38. Sangwan A, Tewari S, Singh H, Sharma RK, Narula SC. Periodontal status and hyperlipidemia: statin users versus non-users. *J Periodontol* 2013;84:3-12.
39. Sayar F, Fallah S, Akhondi N, Jamshidi S. Association of serum lipid indices and statin consumption with periodontal status. *Oral Dis* 2016;22:775-80.
40. Pradeep AR, Kumari M, Rao NS, Martande SS, Naik SB. Clinical efficacy of subgingivally delivered 1.2% atorvastatin in chronic periodontitis: a randomized controlled clinical trial. *J Periodontol* 2013;84:871-9.
41. Pradeep AR, Rao NS, Bajaj P, Kumari M. Efficacy of subgingivally delivered simvastatin in the treatment of patients with type 2 diabetes and chronic periodontitis: a randomized double-masked controlled clinical trial. *J Periodontol* 2013;84:24-31.
42. Pradeep AR, Thorat MS. Clinical effect of subgingivally delivered simvastatin in the treatment

- of patients with chronic periodontitis: a randomized clinical trial. *J Periodontol* 2010;81:214-22.
43. Rosenberg DR, Andrade CX, Chaparro AP, Inostroza CM, Ramirez V, Violant D, et al. Short-term effects of 2% atorvastatin dentifrice as an adjunct to periodontal therapy: a randomized double-masked clinical trial. *J Periodontol* 2015;86:623-30.
  44. Saxlin T, Suominen-Taipale L, Knuutila M, Alha P, Ylöstalo P. Dual effect of statin medication on the periodontium. *J Clin Periodontol* 2009;36:997-1003.
  45. Fentoğlu Ö, Kırzioğlu FY, Bulut MT, Kumbul Doğuç D, Kulaç E, Önder C, et al. Evaluation of lipid peroxidation and oxidative DNA damage in patients with periodontitis and hyperlipidemia. *J Periodontol* 2015;86:682-8.
  46. Stein D, Lee Y, Schmid MJ, Killpack B, Genrich MA, Narayana N, et al. Local simvastatin effects on mandibular bone growth and inflammation. *J Periodontol* 2005;76:1861-70.
  47. Montecucco F, Bertolotto M, Ottonello L, Pende A, Dapino P, Quercioli A, et al. Chlorhexidine prevents hypochlorous acid-induced inactivation of  $\alpha$ 1-antitrypsin. *Clin Exp Pharmacol Physiol* (2009);36:e72-7.
  48. Niemann-Jönsson A, Dimayug P, Joving S, Calara F, Ares MP, Fredrikson GN, et al. Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor- $\alpha$  expression. *Arterioscler Thromb Vasc Biol* 2000; 20:2205-11.
  49. Stapleton PA, Goodwill AG, James ME, Brock RW, Frisbee JC. Hypercholesterolemia and microvascular dysfunction: interventional strategies. *J Inflamm (Lond)* 2010;7:54.
  50. Thomas C E, Jackson R L, Ohlweiler DF, Ku G. Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 beta release from human blood mononuclear cells. *J Lipid Res* 1994;35:417-27.
  51. Zhaoxia L, Chase AJ, Newby AC. Statins Inhibit Secretion of Metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. *Arterioscler Thromb Vasc Biol* 2003;23:769-75.
  52. Koh KK, Son JW, Ahn JY, Jin DK, Kim HS, Choi YM, et al. Comparative Effects of Diet and Statin on NO Bioactivity and Matrix Metalloproteinases in Hypercholesterolemic Patients With Coronary Artery Disease. *Arterioscler Thromb Vasc Biol* 2002;22:e19-23.
  53. Yang H, Feng Y, Luan Y. Determination of Simvastatin in human plasma by liquid chromatography-mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2003;785:369-75.
  54. Sakoda K, Yamamoto M, Negishi Y, Liao JK, Node K, Izumi Y. Simvastatin decreases IL-6 and IL-8 production in epithelial cells. *J Dent Res* 2006;85:520-3.